Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stephen B Heitner

Showing results (51-60 of 107) with videos related to

Pageof 11
Sort By:
Journal of the American Heart Association|May 9, 2023
Clinical Profile, Health Care Costs, and Outcomes of Patients Hospitalized for Heart Failure With Severely Reduced Ejection FractionJosephine Harrington, Jie-Lena Sun, Gregg C Fonarow, et al.
Heart Rhythm|February 22, 2020
Appropriate and inappropriate shocks in hypertrophic cardiomyopathy patients with subcutaneous implantable cardioverter-defibrillators: An international multicenter studyBabak Nazer, Zack Dale, Gianmarco Carrassa, et al.
Heart Rhythm|September 2, 2025
Low Incidence of Atrial Fibrillation in Patients with Obstructive HCM Treated with Aficamten: An Analysis from the REDWOOD-HCM, SEQUOIA-HCM and FOREST-HCM TrialsEthan J Rowin, Martin S Maron, Iacopo Olivotto, et al.
JACC. Heart Failure|February 1, 2024
Tricuspid Regurgitation and Clinical Outcomes in Heart Failure With Reduced Ejection FractionMarianna Adamo, Marco Metra, Brian L Claggett, et al.
Heart Rhythm|December 21, 2021
Importance of newer cardiac magnetic resonance-based risk markers for sudden death prevention in hypertrophic cardiomyopathy: An international multicenter studyEthan J Rowin, Martin S Maron, Arnon Adler, et al.
Journal of Inherited Metabolic Disease|September 6, 2017
Triheptanoin versus trioctanoin for long-chain fatty acid oxidation disorders: a double blinded, randomized controlled trialMelanie B Gillingham, Stephen B Heitner, Julie Martin, et al.
Circulation. Heart Failure|March 3, 2022
Developments in Exercise Capacity Assessment in Heart Failure Clinical Trials and the Rationale for the Design of METEORIC-HFGregory D Lewis, Kieran F Docherty, Adriaan A Voors, et al.
European Heart Journal|August 31, 2025
Serum magnesium and outcomes in heart failure with reduced ejection fraction: the GALACTIC-HF trialMisato Chimura, Kieran F Docherty, Pardeep S Jhund, et al.
Journal of the American College of Cardiology|March 20, 2019
Transthyretin Stabilization by AG10 in Symptomatic Transthyretin Amyloid CardiomyopathyDaniel P Judge, Stephen B Heitner, Rodney H Falk, et al.
JACC. Heart Failure|January 13, 2026
Lactate Dehydrogenase and Outcomes in Patients With HF and Reduced Ejection Fraction: Insights From GALACTIC-HFRyohei Ono, Misato Chimura, Kieran F Docherty, et al.
Pageof 11

Showing results (51-60 of 107) with videos related to

Sort By:
Pageof 11
Journal of the American Heart Association|May 9, 2023
Clinical Profile, Health Care Costs, and Outcomes of Patients Hospitalized for Heart Failure With Severely Reduced Ejection FractionJosephine Harrington, Jie-Lena Sun, Gregg C Fonarow, et al.
Heart Rhythm|February 22, 2020
Appropriate and inappropriate shocks in hypertrophic cardiomyopathy patients with subcutaneous implantable cardioverter-defibrillators: An international multicenter studyBabak Nazer, Zack Dale, Gianmarco Carrassa, et al.
Heart Rhythm|September 2, 2025
Low Incidence of Atrial Fibrillation in Patients with Obstructive HCM Treated with Aficamten: An Analysis from the REDWOOD-HCM, SEQUOIA-HCM and FOREST-HCM TrialsEthan J Rowin, Martin S Maron, Iacopo Olivotto, et al.
JACC. Heart Failure|February 1, 2024
Tricuspid Regurgitation and Clinical Outcomes in Heart Failure With Reduced Ejection FractionMarianna Adamo, Marco Metra, Brian L Claggett, et al.
Heart Rhythm|December 21, 2021
Importance of newer cardiac magnetic resonance-based risk markers for sudden death prevention in hypertrophic cardiomyopathy: An international multicenter studyEthan J Rowin, Martin S Maron, Arnon Adler, et al.
Journal of Inherited Metabolic Disease|September 6, 2017
Triheptanoin versus trioctanoin for long-chain fatty acid oxidation disorders: a double blinded, randomized controlled trialMelanie B Gillingham, Stephen B Heitner, Julie Martin, et al.
Circulation. Heart Failure|March 3, 2022
Developments in Exercise Capacity Assessment in Heart Failure Clinical Trials and the Rationale for the Design of METEORIC-HFGregory D Lewis, Kieran F Docherty, Adriaan A Voors, et al.
European Heart Journal|August 31, 2025
Serum magnesium and outcomes in heart failure with reduced ejection fraction: the GALACTIC-HF trialMisato Chimura, Kieran F Docherty, Pardeep S Jhund, et al.
Journal of the American College of Cardiology|March 20, 2019
Transthyretin Stabilization by AG10 in Symptomatic Transthyretin Amyloid CardiomyopathyDaniel P Judge, Stephen B Heitner, Rodney H Falk, et al.
JACC. Heart Failure|January 13, 2026
Lactate Dehydrogenase and Outcomes in Patients With HF and Reduced Ejection Fraction: Insights From GALACTIC-HFRyohei Ono, Misato Chimura, Kieran F Docherty, et al.
Pageof 11